These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

606 related articles for article (PubMed ID: 33244884)

  • 1. Myosteatosis rather than sarcopenia associates with non-alcoholic steatohepatitis in non-alcoholic fatty liver disease preclinical models.
    Nachit M; De Rudder M; Thissen JP; Schakman O; Bouzin C; Horsmans Y; Vande Velde G; Leclercq IA
    J Cachexia Sarcopenia Muscle; 2021 Feb; 12(1):144-158. PubMed ID: 33244884
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Muscle fat content is strongly associated with NASH: A longitudinal study in patients with morbid obesity.
    Nachit M; Kwanten WJ; Thissen JP; Op De Beeck B; Van Gaal L; Vonghia L; Verrijken A; Driessen A; Horsmans Y; Francque S; Leclercq IA
    J Hepatol; 2021 Aug; 75(2):292-301. PubMed ID: 33865909
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Myosteatosis, but not Sarcopenia, Predisposes NAFLD Subjects to Early Steatohepatitis and Fibrosis Progression.
    Hsieh YC; Joo SK; Koo BK; Lin HC; Lee DH; Chang MS; Park JH; So YH; Kim W;
    Clin Gastroenterol Hepatol; 2023 Feb; 21(2):388-397.e10. PubMed ID: 35101634
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Automated computerized image analysis for the user-independent evaluation of disease severity in preclinical models of NAFLD/NASH.
    De Rudder M; Bouzin C; Nachit M; Louvegny H; Vande Velde G; Julé Y; Leclercq IA
    Lab Invest; 2020 Jan; 100(1):147-160. PubMed ID: 31506634
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatocellular carcinoma in patients with non-alcoholic fatty liver disease is associated with heterogeneous pattern of fat infiltration in skeletal muscles.
    Nachit M; Dioguardi Burgio M; Abyzov A; Garteiser P; Paradis V; Vilgrain V; Leclercq I; Van Beers BE
    Eur Radiol; 2024 Mar; 34(3):1461-1470. PubMed ID: 37658893
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of Visceral Fat Obesity, Sarcopenia, and Myosteatosis with Non-Alcoholic Fatty Liver Disease without Obesity.
    Kim HK; Bae SJ; Lee MJ; Kim EH; Park H; Kim HS; Cho YK; Jung CH; Lee WJ; Choe J
    Clin Mol Hepatol; 2023 Oct; 29(4):987-1001. PubMed ID: 37403320
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bile acids contribute to the development of non-alcoholic steatohepatitis in mice.
    Gillard J; Clerbaux LA; Nachit M; Sempoux C; Staels B; Bindels LB; Tailleux A; Leclercq IA
    JHEP Rep; 2022 Jan; 4(1):100387. PubMed ID: 34825156
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TLR9 is up-regulated in human and murine NASH: pivotal role in inflammatory recruitment and cell survival.
    Mridha AR; Haczeyni F; Yeh MM; Haigh WG; Ioannou GN; Barn V; Ajamieh H; Adams L; Hamdorf JM; Teoh NC; Farrell GC
    Clin Sci (Lond); 2017 Aug; 131(16):2145-2159. PubMed ID: 28687713
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Strain dependence of diet-induced NASH and liver fibrosis in obese mice is linked to diabetes and inflammatory phenotype.
    Farrell GC; Mridha AR; Yeh MM; Arsov T; Van Rooyen DM; Brooling J; Nguyen T; Heydet D; Delghingaro-Augusto V; Nolan CJ; Shackel NA; McLennan SV; Teoh NC; Larter CZ
    Liver Int; 2014 Aug; 34(7):1084-93. PubMed ID: 24107103
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Myosteatosis in nonalcoholic fatty liver disease: An exploratory study.
    De Munck TJI; Verhaegh P; Lodewick T; Bakers F; Jonkers D; Masclee AAM; Verbeek J; Koek GH
    Clin Res Hepatol Gastroenterol; 2021 May; 45(3):101500. PubMed ID: 32828745
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Roles of adipose restriction and metabolic factors in progression of steatosis to steatohepatitis in obese, diabetic mice.
    Larter CZ; Yeh MM; Van Rooyen DM; Teoh NC; Brooling J; Hou JY; Williams J; Clyne M; Nolan CJ; Farrell GC
    J Gastroenterol Hepatol; 2009 Oct; 24(10):1658-68. PubMed ID: 19788606
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of L-ornithine L-aspartate on non-alcoholic steatohepatitis-associated hyperammonemia and muscle alterations.
    Pichon C; Nachit M; Gillard J; Vande Velde G; Lanthier N; Leclercq IA
    Front Nutr; 2022; 9():1051157. PubMed ID: 36466421
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sarcopenia is an independent risk factor for non-alcoholic steatohepatitis and significant fibrosis.
    Koo BK; Kim D; Joo SK; Kim JH; Chang MS; Kim BG; Lee KL; Kim W
    J Hepatol; 2017 Jan; 66(1):123-131. PubMed ID: 27599824
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A dynamic association between myosteatosis and liver stiffness: Results from a prospective interventional study in obese patients.
    Nachit M; Lanthier N; Rodriguez J; Neyrinck AM; Cani PD; Bindels LB; Hiel S; Pachikian BD; Trefois P; Thissen JP; Delzenne NM
    JHEP Rep; 2021 Aug; 3(4):100323. PubMed ID: 34355155
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nonalcoholic Steatohepatitis and HCC in a Hyperphagic Mouse Accelerated by Western Diet.
    Ganguly S; Muench GA; Shang L; Rosenthal SB; Rahman G; Wang R; Wang Y; Kwon HC; Diomino AM; Kisseleva T; Soorosh P; Hosseini M; Knight R; Schnabl B; Brenner DA; Dhar D
    Cell Mol Gastroenterol Hepatol; 2021; 12(3):891-920. PubMed ID: 34062281
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dietary modification dampens liver inflammation and fibrosis in obesity-related fatty liver disease.
    Larter CZ; Yeh MM; Haigh WG; Van Rooyen DM; Brooling J; Heydet D; Nolan CJ; Teoh NC; Farrell GC
    Obesity (Silver Spring); 2013 Jun; 21(6):1189-99. PubMed ID: 23666886
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gasdermin D plays a key role as a pyroptosis executor of non-alcoholic steatohepatitis in humans and mice.
    Xu B; Jiang M; Chu Y; Wang W; Chen D; Li X; Zhang Z; Zhang D; Fan D; Nie Y; Shao F; Wu K; Liang J
    J Hepatol; 2018 Apr; 68(4):773-782. PubMed ID: 29273476
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Harnessing Muscle-Liver Crosstalk to Treat Nonalcoholic Steatohepatitis.
    Chakravarthy MV; Siddiqui MS; Forsgren MF; Sanyal AJ
    Front Endocrinol (Lausanne); 2020; 11():592373. PubMed ID: 33424768
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MicroRNA expression analysis in high fat diet-induced NAFLD-NASH-HCC progression: study on C57BL/6J mice.
    Tessitore A; Cicciarelli G; Del Vecchio F; Gaggiano A; Verzella D; Fischietti M; Mastroiaco V; Vetuschi A; Sferra R; Barnabei R; Capece D; Zazzeroni F; Alesse E
    BMC Cancer; 2016 Jan; 16():3. PubMed ID: 26728044
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adverse muscle composition is linked to poor functional performance and metabolic comorbidities in NAFLD.
    Linge J; Ekstedt M; Dahlqvist Leinhard O
    JHEP Rep; 2021 Feb; 3(1):100197. PubMed ID: 33598647
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.